[Bispecific antibodies: indications and perspectives in onco-hematology].

INDICATIONS AND PERSPECTIVES IN ONCO-HEMATOLOGY. Bispecific antibodies, currently under active development, are a new and effective therapeutic tool in malignant hematological diseases. Those used in clinical practice aim to restore the recognition of tumor cells by immune effector cells, leading to their direct and targeted cytotoxicity through the formation of an immune synapse. The main current indications are acute lymphoblastic leukemias, diffuse large B-cell lymphomas, and multiple myeloma, refractory or in relapsed after conventional treatment. Due to their efficacy and tolerance profile, research on bispecific antibodies is highly active and aims to expand their indications.